Mills, Caitlin E. http://orcid.org/0000-0002-2608-4084
Subramanian, Kartik
Hafner, Marc http://orcid.org/0000-0003-1337-7598
Niepel, Mario http://orcid.org/0000-0003-1415-6295
Gerosa, Luca
Chung, Mirra
Victor, Chiara
Gaudio, Benjamin
Yapp, Clarence
Nirmal, Ajit J.
Clark, Nicholas
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U54-CA225088, U54-HL127365, U24-DK116204)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 27 August 2021
Accepted: 6 October 2022
First Online: 14 November 2022
Competing interests
: P.K.S. is a co-founder and member of the BOD of Glencoe Software, a member of the BOD for Applied Biomath, and a member of the SAB for RareCyte, NanoString and Montai Health; he holds equity in Glencoe, Applied Biomath and RareCyte. P.K.S. is a consultant for Merck and the Sorger lab has received research funding from Novartis and Merck in the past five years. Sorger declares that none of these relationships have influenced the content of this manuscript. K.S. is currently an employee of Bristol Myers Squibb, M.H. and L.G. are currently employees of Genentech, and M.N. is currently an employee of Ribon Therapeutics. The other authors declare no competing interests.